Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.
Phase III
RET fusion-positive lung cancer
Status
Positive
Sponsor
Eli Lilly
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The Phase 3 LIBRETTO-432 trial results for Retevmo demonstrate a significant reduction in disease recurrence, which could reshape treatment paradigms in early-stage RET fusion-positive lung cancer. This positions Retevmo as a leading option in a competitive market, warranting close attention from pharma strategy teams.
Recommended action
Humanexa recommends Investigate: The recommended action to investigate is due to the need for deeper analysis of the trial results and their implications on clinical practice and competitive positioning in the oncology market.
Analysis
Monitor upcoming presentations of full trial data and any changes in treatment guidelines regarding RET fusion testing.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.